Deep-learning nomogram reproduced 3D treated volume for prostate HDR brachytherapy QA
A 3D deep-learning nomogram predicted the clinical prescription isodose with high spatial agreement, adding geometry-aware verification to post-plan QA.
Tag
hdr-brachytherapy
Salvage HDR brachytherapy delayed systemic therapy after isolated seminal vesicle recurrence
In 22 patients, salvage HDR brachytherapy produced 40.5% five-year relapse-free survival but 18% developed grade ≥3 GU toxicity.
PTSD symptom burden affected 29% after cervical cancer HDR brachytherapy
Nearly three in ten surveyed cervical cancer survivors reported partial-to-probable PTSD symptoms several years after HDR brachytherapy.
Higher HDR prostate D90 did not improve long-term biochemical control once coverage was adequate
Across 286 HDR monotherapy patients, higher EQD2 D90 was not associated with biochemical control or overall survival.
Single-fraction 15 Gy HDR boost achieved 94% six-year biochemical control in localized prostate cancer
In 607 predominantly high-risk patients, 15 Gy HDR boost plus EBRT produced durable six-year disease control with low severe late toxicity.
Motorized sagittal 3D ultrasound reduced scan variability in prostate HDR brachytherapy
Motorized probe rotation improved sagittal 3D ultrasound consistency and eliminated significant inter-operator variability seen with manual acquisition.
Two salvage HDR brachytherapy schedules produced similar outcomes in recurrent prostate cancer
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
Iridium-192 remains the best-supported HDR source for breast brachytherapy
Iridium-192 has the strongest long-term breast brachytherapy evidence; cobalt-60 is dosimetrically comparable, while ytterbium-169 remains clinically unvalidated.
Endorectal HDR brachytherapy produced 80% initial response in frail rectal cancer
Short-course EBRT plus endorectal HDR brachytherapy produced 80% cCR/ncCR, but grade 3 late rectal toxicity occurred in 27%.
One-week HDR brachytherapy shortened cervical cancer treatment without higher reported toxicity
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
CT-based cervical brachytherapy achieved 84% five-year local control
Routine CT-based adaptive brachytherapy achieved 84.4% five-year local control despite 56.9% of patients having stage III–IV cervical cancer.
Salvage HDR brachytherapy had low severe toxicity but limited five-year biochemical control
Five-year PSA progression-free survival was 24.8% after two-fraction salvage HDR brachytherapy without androgen deprivation, despite low severe toxicity.
STAMP accelerated gynecologic brachytherapy planning without compromising dosimetry
The standardized workflow generated clinically comparable interstitial brachytherapy plans in a median of 10 minutes versus 28 minutes for manual planning.
Patient-specific 3D-printed templates enabled efficient brachytherapy for complex cervical cancer
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
Virtual reality increased confidence after HDR prostate brachytherapy training
Brief virtual-reality training increased self-reported procedural confidence, but knowledge, technical skill, retention, and clinical performance were not tested.